Metabolomics and detection of colorectal cancer in humans: a systematic review.

Metabolomics represents one of the new omics sciences and capitalizes on the unique presence and concentration of small molecules in tissues and body fluids to construct a 'fingerprint' that can be unique to the individual and, within that individual, unique to environmental influences, including health and disease states. As such, metabolomics has the potential to serve an important role in diagnosis and management of human conditions. Colorectal cancer is a major public health concern. Current population-based screening methods are suboptimal and whether metabolomics could represent a new tool of screening is under investigation. The purpose of this systematic review is to summarize existing literature on metabolomics and colorectal cancer, in terms of diagnostic accuracies and distinguishing metabolites. Eight studies are included. A total of 12 metabolites (taurine, lactate, choline, inositol, glycine, phosphocholine, proline, phenylalanine, alanine, threonine, valine and leucine) were found to be more prevalent in colorectal cancer and glucose was found to be in higher proportion in control specimens using tissue metabolomics. Serum and urine metabolomics identified several other differential metabolites between controls and colorectal cancer patients. This article highlights the novelty of the field of metabolomics in colorectal oncology.

[1]  Oliver Fiehn,et al.  A comprehensive urinary metabolomic approach for identifying kidney cancerr. , 2007, Analytical biochemistry.

[2]  Jing Hong,et al.  Technology of metabonomics and its application in gastrointestinal cancer , 2008 .

[3]  Oliver Fiehn,et al.  Metabolite profiling of human colon carcinoma – deregulation of TCA cycle and amino acid turnover , 2008, Molecular Cancer.

[4]  Donald G Robertson,et al.  Metabonomics in toxicology: a review. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.

[5]  R Somorjai,et al.  Detecting colorectal cancer by 1H magnetic resonance spectroscopy of fecal extracts , 2009, NMR in biomedicine.

[6]  A. Zell,et al.  Metabonomics in cancer diagnosis: mass spectrometry-based profiling of urinary nucleosides from breast cancer patients , 2008 .

[7]  Tianlu Chen,et al.  Urinary metabonomic study on colorectal cancer. , 2010, Journal of proteome research.

[8]  Rachel Cavill,et al.  Metabolic profiling of human colorectal cancer using high-resolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). , 2009, Journal of proteome research.

[9]  Tianlu Chen,et al.  Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. , 2009, Journal of proteome research.

[10]  Daniel Monleón,et al.  Metabolite profiling of fecal water extracts from human colorectal cancer , 2009, NMR in biomedicine.

[11]  T. Kieber‐Emmons,et al.  Applying in vitro NMR spectroscopy and 1H NMR metabonomics to breast cancer characterization and detection , 2005 .

[12]  Kevin F Krenitsky,et al.  Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection , 2010, BMC medicine.

[13]  Leo L. Cheng,et al.  Metabolic characterization of human prostate cancer with tissue magnetic resonance spectroscopy. , 2005, Cancer research.

[14]  Douglas B Kell,et al.  Metabolomic biomarkers: search, discovery and validation , 2007, Expert review of molecular diagnostics.

[15]  R. Weinshilboum,et al.  Metabolomics: a global biochemical approach to drug response and disease. , 2008, Annual review of pharmacology and toxicology.

[16]  K. Krishnan,et al.  Metabolomic mapping of atypical antipsychotic effects in schizophrenia , 2007, Molecular Psychiatry.

[17]  Douglas K Rex,et al.  American College of Gastroenterology Guidelines for Colorectal Cancer Screening 2008 , 2022 .

[18]  A. Neville,et al.  Cost‐effectiveness of colorectal cancer screening: Comparison of community‐based flexible sigmoidoscopy with fecal occult blood testing and colonoscopy , 2004, Journal of gastroenterology and hepatology.

[19]  A. Imperiale,et al.  Metabolic characterization of primary human colorectal cancers using high resolution magic angle spinning 1H magnetic resonance spectroscopy , 2009, Metabolomics.

[20]  R. Hunt,et al.  Canadian Association of Gastroenterology and the Canadian Digestive Health Foundation: Guidelines on colon cancer screening. , 2004, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[21]  I. Bertini,et al.  Metabolomics: available results, current research projects in breast cancer, and future applications. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Jostein Halgunset,et al.  Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy , 2008, Molecular Cancer.

[23]  P. Bossuyt,et al.  BMC Medical Research Methodology , 2002 .

[24]  Roberto Canaparo,et al.  Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. , 2004, Pharmacological research.

[25]  J. Habbema,et al.  Population Screening for Colorectal Cancer: Faeces, Endoscopes or X-Rays? , 2007, Cellular oncology : the official journal of the International Society for Cellular Oncology.

[26]  A. Ciampi,et al.  Adherence to colorectal cancer screening guidelines in Canada , 2007, BMC gastroenterology.

[27]  R. Hilsden,et al.  Low Uptake of Colorectal Cancer Screening 3 Yr After Release of National Recommendations for Screening , 2007, The American Journal of Gastroenterology.

[28]  T. Bathen,et al.  MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade, and hormone status , 2007, Breast Cancer Research and Treatment.

[29]  A. Zell,et al.  Bioinformatical evaluation of modified nucleosides as biomedical markers in diagnosis of breast cancer. , 2008, Analytica chimica acta.

[30]  Ya-li Liu,et al.  Intravenous pantoprazole as an adjuvant therapy following successful endoscopic treatment for peptic ulcer bleeding. , 2009, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[31]  D. Kell,et al.  Metabolomics by numbers: acquiring and understanding global metabolite data. , 2004, Trends in biotechnology.

[32]  L. Rabeneck,et al.  A Population-Based Estimate of the Extent of Colorectal Cancer Screening in Ontario , 2004, American Journal of Gastroenterology.

[33]  Elaine Holmes,et al.  Topographical variation in metabolic signatures of human gastrointestinal biopsies revealed by high-resolution magic-angle spinning 1H NMR spectroscopy. , 2007, Journal of proteome research.

[34]  Quantitative Pathology in Tissue MR Spectroscopy Based Human Prostate Metabolomics , 2004, Technology in cancer research & treatment.

[35]  C. Mountford,et al.  Assessment of human colorectal biopsies by 1H MRS: Correlation with histopathology , 1993, Magnetic resonance in medicine.

[36]  David I. Ellis,et al.  Metabolomics: Current analytical platforms and methodologies , 2005 .

[37]  Ian D Wilson,et al.  Analytical strategies in metabonomics. , 2007, Journal of proteome research.